TNG-348

N/A

Report date: 2025/06/10 17:55:07
NME

Base Information

Drug NameTNG-348
Drug Alias NameTNG348TNG-348USP-1
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUbiquitin carboxyl-terminal hydrolase 1 inhibitors
TargetsUbiquitin carboxyl-terminal hydrolase 1
Therapy Area/IndicationsProstatic NeoplasmsOvarian NeoplasmsPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedivir AB
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTango Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsOvarian NeoplasmsPancreatic Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A